PepGen Phase 2 trial stymied by an outlier Read in browser

Thank you for reading, dupa dupackia! basic Subscription UPGRADE

M Tue W Th F 31 March, 2026

AI has gone from buzzword to pipeline strategy — but are the results a mixed bag? We're talking to the researchers in the thick of it about what's moving the needle, what's stalling out and what comes next. Join us for a free virtual program, then continue the conversation at an in-person-only fireside and happy hour in Boston. Choose your pass.

presented by Health Eco­nom­ic Out­comes of the On­co­type DX Breast Re­cur­rence Test at a Pop­u­la­tion Health Lev­el

SPOTLIGHT Live today: MAHA, vaccine politics and the risk for Republicans — with former Congressman Michael Burgess

news Eli Lilly to buy Centessa for $6.3B to get sleep disorder drug Biogen to acquire Apellis for $5.6B PepGen’s muscle disease program posts poor mid-stage results as one patient's data gets markedly worse Exclusive: First clinical trial of tRNA therapy, a new disease-agnostic form of genetic medicine, will start soon Exclusive: In promising early readout, Enveda shows Dupixent-rivaling potential in atopic dermatitis Exclusive: ViiV R&D head Kimberly Smith heads to retirement after three decades in HIV care

Head of Regulatory Strategy TCG stealth clinic-ready newco Boston, MA, USA Senior Director, Licensing Officer Bayer Cambridge, MA, USA Recruit talent with Endpoints Careers Contact Meg Estacio: mestacio@endpointsnews.com

John Carroll’s R&D 15 report is back — and this year, he’s bringing some of the industry’s top research chiefs into the conversation to break down what the data means, what’s shifting, and where biopharma R&D is headed. Join us to find out what comes next.

ENDPOINTS PHARMA White House overtures to pharma on new pricing talks met with frosty reception Merck touts comparator data for oral cholesterol drug #AAD26: What you need to know from Takeda, Alumis, Priovant and Incyte Samsung Bio union workers threaten strike over pay, disclosure of employee data Merck leans toward lower Winrevair dose for pivotal trial in rare form of heart failure

in case you missed it 1. Blackstone raises $6.3B life sciences fund in record fundraising haul 2. Sanofi reports underwhelming Phase 3 OX40 data in eczema, second case of Kaposi’s sarcoma 3. 'A bit of a surprise': Kardigan's repeat dosing of blood pressure drug has no benefit over single shot 4. Braveheart Bio posts promising China data in heart disease where Bristol Myers, Cytokinetics have drugs 5. Viridian’s autoimmune eye disease shot passes Phase 3, but can it compete with Amgen? 6.